Weekly Research Analysts’ Ratings Changes for Janux Therapeutics (JANX)

Several brokerages have updated their recommendations and price targets on shares of Janux Therapeutics (NASDAQ: JANX) in the last few weeks:

• 11/12/2026 – Janux Therapeutics had its “buy” rating reaffirmed by Citigroup.
• 11/12/2026 – Janux Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 11/12/2026 – Janux Therapeutics was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 11/6/2026 – Janux Therapeutics had its price target raised by Truist Financial from $26.00 to $27.00. They now have a “buy” rating on the stock.
• 11/6/2026 – Janux Therapeutics had its price target raised by Wedbush from $36.00 to $40.00. They now have an “outperform” rating on the stock.
• 11/6/2026 – Janux Therapeutics had its price target raised by Barclays from $14.00 to $15.00. They now have an “underweight” rating on the stock.
• 10/19/2026 – Janux Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 10/16/2026 – Janux Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $11.49 on Friday. The business has a fifty day simple moving average of $16.97 and a two-hundred day simple moving average of $15.37. Janux Therapeutics, Inc. has a 1 year low of $11.45 and a 1 year high of $35.34. The company has a market capitalization of $702.96 million, a price-to-earnings ratio of -7.23 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.13. The company had revenue of $9.29 million during the quarter, compared to analyst estimates of $8.03 million. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors. Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.